A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer-Reference-Cited by-同舟云学术

A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer

Published:2019-03 Issue:7 Volume:15 Page:717-726
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Takahashi Shunji¹,Kiyota Naomi²,Yamazaki Tomoko³,Chayahara Naoko²,Nakano Kenji¹,Inagaki Lina¹,Toda Kazuhisa⁴,Enokida Tomohiro⁵,Minami Hironobu²,Imamura Yoshinori²,Fukuda Naoki¹,Sasaki Tatsuya⁶,Suzuki Takuya⁶,Ikezawa Hiroki⁶,Dutcus Corina E⁷,Tahara Makoto⁵

Affiliation:

1. Department of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan

2. Department of Medical Oncology & Hematology/Cancer Center, Kobe University Hospital, Kobe, Japan

3. Department of Head & Neck Oncology, Miyagi Cancer Center, Miyagi, Japan

4. Department of Head & Neck Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan

5. Department of Head & Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan

6. Eisai Co. Ltd, Tokyo, Japan

7. Eisai Inc., Woodcliff Lake, NJ 07677, USA

Abstract

Aim: To investigate the safety and efficacy of lenvatinib in advanced thyroid cancer. Patients/methods: In this Phase II study, 51 Japanese patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC), medullary thyroid cancer (MTC) or anaplastic thyroid cancer (ATC) received once-daily lenvatinib 24 mg. The primary end point was safety. Results: All patients experienced ≥1 adverse event (AE); only one patient experienced an AE leading to discontinuation. The most common any-grade AEs were hypertension, decreased appetite, palmar-plantar erythrodysesthesia, fatigue and proteinuria. Response rates for RR-DTC: 68%; MTC: 22%; ATC: 24%. Median progression-free survival for RR-DTC: 25.8 months; MTC: 9.2 months; ATC: 7.4 months. Conclusion: Lenvatinib demonstrated a manageable safety profile, proven antitumor activity in RR-DTC and promising efficacy in MTC and ATC. Clinical trial registration: clinicaltrials.gov NCT01728623

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2018-0557

Reference30 articles.

1. Thyroid Cancer Incidence Patterns in the United States by Histologic Type, 1992–2006

2. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Thyroid Carcinoma. Version 2.2017. www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf.

3. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions

4. Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy

5. Cabozantinib in Progressive Medullary Thyroid Cancer

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Bioequivalence Trial of Lenvatinib Mesylate Capsules in Healthy Subjects Under Fasting and Postprandial Conditions;Clinical Pharmacology in Drug Development;2024-09-10

2. Anaplastic thyroid cancer: A review of recent evidence and summary of an Australian institutional protocol;Asia-Pacific Journal of Clinical Oncology;2024-08-15

3. Recent Trends and Potential of Radiotherapy in the Treatment of Anaplastic Thyroid Cancer;Biomedicines;2024-06-10

4. A Prospective Cohort Study Exploring the Effect of Lenvatinib Planned Drug Holidays in Treatment of Differentiated Thyroid Cancer;Thyroid®;2024-05-01

5. Donafenib as neoadjuvant therapy in locally advanced thyroid cancer: protocol for the DONATHYCA phase II prospective single-arm trial in China;BMJ Open;2024-05